Impact of Lot-to-Lot Variability of Cation Exchange Chromatography Resin on Process Performance - A case study to understand the impact of lot-to-lot variability of a cation exchange resin on process


Impact of Lot-to-Lot Variability of Cation Exchange Chromatography Resin on Process Performance
A case study to understand the impact of lot-to-lot variability of a cation exchange resin on process performance.

BioPharm International
Volume 21, Issue 5

Impact of Different Elution Profiles on Viral Filtration Step

Figure 8. Effect of conductivity on volumetric flux across an NFP filter
As mentioned above, the CEX step is followed by a viral filtration using a normal flow parvovirus (NFP) filter is subsequently used in the downstream step. During the development of this process step, it was determined that controlling the concentration of NFP load to approximately 8.5 mg/mL and diluting the concentrated cation exchange product with a lower conductivity cation exchange equilibration buffer to reduce the conductivity resulted in the optimal performance of this viral filtration step. However, a consequence of having a wider than usual elution peak is a lower product concentration and a higher elution volume, allowing little or no dilution with the equilibration buffer because of volumetric constraints in a manufacturing process. This could result in a higher conductivity load for the NFP step. A higher conductivity load has the potential to impact the flux across the filtration process, as shown in Figure 8.

Process Development and Manufacturing Considerations

It may be possible to overcome the problem of lot-to-lot variability in resin particle size so that the cation exchange step and subsequent steps are not affected. A suitable resin defining process could potentially remove the smaller particles, making the resin lots much more uniform. Although such a process would likely produce a more normal elution profile, it could be expensive in terms of the volume of resin discarded.


In this study, significant visual differences in elution profile and product volume were observed for the resin lots that had > 10% of particles smaller than 40 μm. Concomitantly, there is an increase in product volume on elution with an increase in the percentage of smaller particles. This increase in product volume generally parallels the increase in the asymmetry factor measured with 1 M NaCl as the analyte. Studies with higher strength elution buffer and acetone rule out differences in column packing as possible causes of the variable elution profiles. Instead, the unusual elution profile is likely caused by higher accessibility of the antibody to the charged sites inside the pores. This higher accessibility is probably caused by the shorter diffusional length inside the pores of smaller particles. An effect of this is probably a stronger interaction and more resolution of the charged isoforms of the antibody, resulting in a broader elution profile. Despite these differences, performance of the cation exchange step was not affected. No differences in yield, clearance of the impurities, or the distribution of charged isoforms were observed for these lots. However, an increase in the cation exchange pool conductivity was observed and this could impact the volumetric flux across the subsequent viral filtration step, especially at higher volumetric loadings.

Jane Wahome is a former development engineer from PDL BioPharma, Brooklyn Park, MN,
Weichang Zhou, PhD, is the senior director, bioprocess engineering, technology development, at Genzyme, Framingham, MA, and Amitava Kundu, PhD, is the associate director, process development at GenMab, Brooklyn Park, MN.

blog comments powered by Disqus



First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here